These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28487868)

  • 1. Severe symptomatic acute hyponatremia in traumatic brain injury responded very rapidly to a single 15 mg dose of oral tolvaptan; a Mayo Clinic Health System hospital experience - need for caution with tolvaptan in younger patients with preserved renal function.
    Onuigbo MAC; Agbasi N
    J Renal Inj Prev; 2017; 6(1):26-29. PubMed ID: 28487868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A; McCormick L; Rahman M
    Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan.
    Hanna RM; Velez JC; Rastogi A; Nguyen MK; Kamgar MK; Moe K; Arman F; Hasnain H; Nobakht N; Selamet U; Kurtz I
    Kidney Med; 2020; 2(1):20-28. PubMed ID: 32734225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
    Arima H; Goto K; Motozawa T; Mouri M; Watanabe R; Hirano T; Ishikawa SE
    Endocr J; 2021 Jan; 68(1):17-29. PubMed ID: 32863282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Verbalis JG; Greenberg A; Burst V; Haymann JP; Johannsson G; Peri A; Poch E; Chiodo JA; Dave J
    Am J Med; 2016 May; 129(5):537.e9-537.e23. PubMed ID: 26584969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
    Park GH; Lee CM; Song JW; Jung MC; Kim JK; Song YR; Kim HJ; Kim SG
    Korean J Intern Med; 2018 May; 33(3):561-567. PubMed ID: 28286940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
    Shoaf SE; Bricmont P; Dandurand A
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Hyponatremia with Tolvaptan in a Patient after Neurosurgical Treatment of a Pituitary Tumor: Case Report and Review of Literature.
    Ichimura S; Fahlbusch R; Lüdemann W
    J Neurol Surg Rep; 2015 Nov; 76(2):e279-81. PubMed ID: 26623242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
    De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
    Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose.
    Torres AC; Wickham EP; Biskobing DM
    Endocr Pract; 2011; 17(4):e97-100. PubMed ID: 21613055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with Tolvaptan for Euvolemic and Hypervolemic Hyponatremia in the Acute Care Setting.
    Olin JL; Mitchell G; Cremisi H
    Hosp Pharm; 2015 May; 50(5):380-5. PubMed ID: 26405324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyponatremia and tolvaptan : what is the situation 5 years after approval?].
    Hensen J
    Internist (Berl); 2015 Jul; 56(7):760-72. PubMed ID: 25963933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C; Lesch C; Berger K
    Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study.
    Berardi R; Mastroianni C; Lo Russo G; Buosi R; Santini D; Montanino A; Carnaghi C; Tiseo M; Chiari R; Camerini A; Barni S; De Marino V; Ferrari D; Cristofano A; Doni L; Freddari F; Fumagalli D; Portalone L; Sarmiento R; Schinzari G; Sperandi F; Tucci M; Inno A; Ciuffreda L; Mariotti M; Mariani C; Caramanti M; Torniai M; Gallucci R; Bennati C; Bordi P; Buffoni L; Galeassi A; Ghidini M; Grossi E; Morabito A; Vincenzi B; Arvat E
    Ther Adv Med Oncol; 2019; 11():1758835919877725. PubMed ID: 31632468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.